Zobrazeno 1 - 10
of 14
pro vyhledávání: '"N. Yu. Ivashkina"'
Autor:
V. T. Ivashkin, A. V. Gorelov, D. I. Abdulganieva, O. P. Alekseeva, S. A. Alekseenko, A. Yu. Baranovsky, I. N. Zakharova, O. Yu. Zolnikova, K. V. Ivashkin, N. Yu. Ivashkina, N. V. Korochanskaya, S. N. Mammaev, S. V. Nikolaeva, E. A. Poluektova, A. S. Trukhmanov, D. V. Usenko, I. B. Khlynov, V. V. Tsukanov, O. S. Shifrin, I. V. Berezhnaya, T. L. Lapina, R. V. Maslennikov, N. G. Sugian, A. I. Ulyanin
Publikováno v:
Российский журнал гастроэнтерологии, гепатологии, колопроктологии, Vol 34, Iss 4, Pp 113-136 (2024)
Aim: to optimize outcomes of the treatment and prevention of gastrointestinal diseases in adults and children. Key points. The Methodological Guidelines contain sections on the terminology, classification, mechanisms of action, requirements for sale
Externí odkaz:
https://doaj.org/article/94395aeb4ee74851bc51eaf47057103f
Autor:
V. T. Ivashkin, I. V. Maev, D. I. Abdulganieva, S. A. Alekseenko, A. V. Gorelov, I. N. Zakharova, O. Yu. Zolnikova, N. Yu. Ivashkina, N. V. Korochanskaya, S. N. Mammayev, E. A. Poluektova, A. S. Trukhmanov, D. V. Usenko, Yu. P. Uspensky, V. V. Tsukanov, O. S. Shifrin, I. V. Berezhnaya, K. V. Ivashkin, T. L. Lapina, R. V. Maslennikov, S. V. Nikolaeva, N. G. Sugyan, A. I. Ulyanin
Publikováno v:
Российский журнал гастроэнтерологии, гепатологии, колопроктологии, Vol 31, Iss 2, Pp 65-91 (2021)
Aim. The practical guidelines are intended for primary care physicians, general practitioners, paediatricians, gastroenterologists and general internists to advance the treatment and prevention of gastroenterological diseases in adults and children i
Externí odkaz:
https://doaj.org/article/694975bb6c7c4fe2930cd053448ab306
Publikováno v:
Терапевтический архив, Vol 92, Iss 8, Pp 108-117 (2020)
Among the many causes of the inflammatory process in the esophagus, infectious diseases are becoming increasingly important due to their steady growth. Previously esophageal infections have traditionally been associated with immunodeficiency syndrome
Externí odkaz:
https://doaj.org/article/39b570fe5eb64bdb9000ac26cab2d427
Autor:
V. T. Ivashkin, I. V. Mayev, D. I. Abdulganieva, S. A. Alekseenko, N. Yu. Ivashkina, N. V. Korochanskaya, S. N. Mammaev, E. A. Poluektova, A. S. Trukhmanov, Yu. P. Uspensky, V. V. Tsukanov, O. S. Shifrin, O. Yu. Zolnikova, K. V. Ivashkin, T. L. Lapina, R. V. Maslennikov, A. I. Ulyanin
Publikováno v:
Российский журнал гастроэнтерологии, гепатологии, колопроктологии, Vol 30, Iss 2, Pp 76-89 (2020)
Aim. To provide practical recommendations on the use of probiotics for the treatment and prevention of gastroenterological diseases in adults.General provisions. Probiotics are living microorganisms that benefit the health of the host when administer
Externí odkaz:
https://doaj.org/article/68b42d7e6d0d4c5194f247b5484cb5ff
Autor:
V. T. Ivashkin, I. V. Maev, A. S. Trukhmanov, T. L. Lapina, D. N. Andreev, E. K. Baranskaya, A. S. Tertychny, S. S. Pirogov, A. A. Sheptulin, D. I. Abdulganieva, D. T. Dicheva, A. V. Zaborovsky, N. Yu. Ivashkina, N. V. Korochanskaya, A. V. Paraskevova
Publikováno v:
Российский журнал гастроэнтерологии, гепатологии, колопроктологии, Vol 28, Iss 6, Pp 84-98 (2019)
Aim. This paper presents guidelines on the diagnostics and treatment of eosinophilic esophagitis, which can be used by practitioners in their everyday practice.Summary. Eosinophilic esophagitis (EoE) is a chronic immune-mediated disease of the esopha
Externí odkaz:
https://doaj.org/article/a5ffa39d2f9840ffa363f23528a8c5b8
Autor:
S. Yu. Raskin, G. B. Kolyvanov, A. A. Litvin, P. O. Bochkov, R. V. Shevchenko, V. V. Smirnov, O. G. Grybakina, A. A. Novitskyi, V. P. Zherdev, L. G. Kolik, T. A. Gudasheva, N. Yu. Ivashkina
Publikováno v:
Фармакокинетика и Фармакодинамика, Vol 0, Iss 3, Pp 20-25 (2017)
Results of pharmacokinetic study of a new dipeptide anxiolytic GB-115 in rats, rabbits and volunteers were presented. After oral drug administration significant differences were found. For example, a dose-independent parameter - the elimination rate
Externí odkaz:
https://doaj.org/article/d65efaf708494369b9b6486e71bb1101
Autor:
V. P. Zherdev, G. B. Kolyvanov, A. A. Litvin, V. V. Smirnov, L. G. Kolik, S. Yu. Raskin, N. Yu. Ivashkina, T. A. Gudasheva, S. B. Seredenin
Publikováno v:
Фармакокинетика и Фармакодинамика, Vol 0, Iss 1, Pp 52-56 (2017)
Pharmacokinetic study of а new original anxiolytic drug GB-115, developed on the basis of endogenous tetrapeptide cholecystokinin, in healthy volunteers was performed. Volunteers were received drug as single 1, 3, 7, 11 or 15 mg tablets. The parent
Externí odkaz:
https://doaj.org/article/0f5cfb960ca84a2f9d542ab9e0128e95
Publikováno v:
Российский журнал гастроэнтерологии, гепатологии, колопроктологии, Vol 25, Iss 5, Pp 16-24 (2015)
Aim of investigation. To analyze efficacy of heartburn relief and pathological gastroesophageal reflux (GER) elimination as well as dynamics of endoscopic changes at gastroesophageal reflux disease (GERD) under dioctaedric smectite (Smecta) treatment
Externí odkaz:
https://doaj.org/article/152de0ce70df4bc7beebd7ce49d7e88f
Autor:
L. G. Kolik, G. B. Kolyvanov, O. G. Gribakina, T. A. Gudasheva, A. A. Litvin, V. V. Smirnov, R. V. Shevchenko, P. O. Bochkov, V. P. Zherdev, N. Yu. Ivashkina, S. Yu. Raskin
Publikováno v:
Pharmaceutical Chemistry Journal. 53:685-688
Results from an interspecies scaling study of the elimination half-lives of the anxiolytic GB-115 and the antipsychotic dilept in rats, rabbits, and humans are presented. The elimination half-lives of the studied drugs are calculated in real (chronol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a9d3d8d09bb610f9e19ef7aabec79205
https://doi.org/10.1007/s11094-019-02063-3
https://doi.org/10.1007/s11094-019-02063-3
Autor:
S V Minaev, M. V. Metlina, G G Neznamov, S B Seredenin, Dorofeeva Oa, N Yu Ivashkina, T S Syunyakov, V A Martyanov
Publikováno v:
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 119(8)
To evaluate anxiolytic action of GB-115, a low-affinity blocker of central cholecystokinin receptors, used in tablets in a dose of 1 mg for the treatment of patients with anxiety disorders in order to determine effective dose, safety, tolerability an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::75a417a4a6b55768d3970505a4cf7ec0
https://pubmed.ncbi.nlm.nih.gov/31626171
https://pubmed.ncbi.nlm.nih.gov/31626171